Pyxis Oncology, Inc.(PYXS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PYXS Pyxis Oncology, Inc.

交易中 09-16 11:10:49 EDT

3.38

+0.05

+1.50%

最高3.42	最低3.33	成交量11.21万
今开3.34	昨收3.33	日振幅2.70%
总市值2.82亿	流通市值1.68亿	总股本8,341万
成交额37.70万	换手率0.23%	流通股本4,956万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PYXS","market":"US","secType":"STK","nameCN":"Pyxis Oncology, Inc.","latestPrice":3.38,"timestamp":1789571411672,"preClose":3.33,"halted":0,"volume":112149,"delay":0,"changeRate":0.015015015015014961,"floatShares":49560700,"shares":83408050,"eps":-1.402851,"marketStatus":"交易中","change":0.05,"latestTime":"09-16 11:10:49 EDT","open":3.34,"high":3.42,"low":3.33,"amount":377026.2764064,"amplitude":0.027027,"askPrice":3.4,"askSize":1000,"bidPrice":3.37,"bidSize":380,"shortable":3,"etf":0,"ttmEps":-1.402851,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":3.33,"preHourTrading":{"tag":"盘前","latestPrice":3.3519,"preClose":3.33,"latestTime":"08:42 EDT","volume":391,"amount":1349.7357927,"timestamp":1789562529929,"change":0.0219,"changeRate":0.006577,"amplitude":0.045045},"postHourTrading":{"tag":"盘后","latestPrice":3.4778,"preClose":3.33,"latestTime":"19:55 EDT","volume":714,"amount":2430.6723,"timestamp":1789516540257,"change":0.1478,"changeRate":0.044384,"amplitude":0.044384},"volumeRatio":0.292355,"impliedVol":2.4644,"impliedVolPercentile":0.7171},"requestUrl":"/m/hq/s/PYXS","defaultTab":"news","newsList":[{"id":"1183567939","title":"Pyxis Oncology：未见新增安全警示，剂量上限策略降低高体重患者不良事件发生","url":"https://stock-news.laohu8.com/highlight/detail?id=1183567939","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183567939?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:02","pubTimestamp":1788951769,"startTime":"0","endTime":"0","summary":"Pyxis Oncology最新披露的临床数据显示，并未观察到任何新增的安全警示信号。在用药管理层面，针对高体重患者群体所实施的剂量封顶方案，显著减少了不良事件的出现频率。这一发现为该公司在研药物的安全性评估提供了积极的佐证，同时也为特定患者人群的用药策略优化指明了新的方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116282272","title":"Pyxis Oncology发布Micvotabart Pelidotin（Micvo）二线及以上复发/转移性头颈部鳞状细胞癌（2L+ R/M HNSCC）1期单药研究积极更新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1116282272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116282272?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:01","pubTimestamp":1788951675,"startTime":"0","endTime":"0","summary":"Pyxis Oncology宣布其Micvotabart Pelidotin（Micvo）在二线及以上复发/转移性头颈部鳞状细胞癌（2L+ R/M HNSCC）患者中的1期单药研究，公布了积极的最新数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131626120","title":"Pyxis Oncology旗下Micvo在1期临床试验中展现36%确认客观缓解率与94%疾病控制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1131626120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131626120?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:01","pubTimestamp":1788951674,"startTime":"0","endTime":"0","summary":"Pyxis Oncology宣布，其研发管线中的关键候选药物Micvo在1期临床试验中交出了亮眼答卷——确认客观缓解率（ORR）达到36%，疾病控制率（DCR）则高达94%。这一数据不仅彰显了该药物在抗肿瘤活性方面的潜力，也为其后续开发进程注入了强劲动力。值得注意的是，上述结果已获得临床确认，标志着Micvo在早期研究中展现出了令人瞩目的治疗前景。公司方面表示，这些积极信号将为下一阶段的临床试验设计提供重要参考依据。随着数据的进一步积累与解析，市场对Micvo的期待值正在持续升温。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163840087","title":"Pyxis Oncology公布中期无进展生存期为6.2个月，12个月总生存概率达79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163840087","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163840087?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:01","pubTimestamp":1788951672,"startTime":"0","endTime":"0","summary":"Pyxis Oncology, Inc.近日披露了其最新临床试验数据，结果显示患者的中位无进展生存期达到了6.2个月。Pyxis Oncology此番公布的数据，不仅展现了其在研药物的潜力，也为后续研究提供了坚实的数据支撑。随着数据的进一步验证，Pyxis Oncology有望在竞争激烈的肿瘤药物市场中占据一席之地。总而言之，Pyxis Oncology此次披露的中期结果，为患者和投资者都带来了希望，也为公司的研发管线增添了新的看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173359674","title":"Pyxis Oncology公布2026年第二季度财报，推动Micvo迈向关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1173359674","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173359674?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:01","pubTimestamp":1786618877,"startTime":"0","endTime":"0","summary":"Pyxis Oncology, Inc. 发布了2026年第二季度财务业绩，并同步推进其核心候选药物Micvo，向着2026年关键临床里程碑迈进。这家专注于肿瘤领域的生物制药公司，正通过一系列战略举措，强化其管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145924428","title":"Pyxis Oncology获BVF Partners领投融资，GordonMD Global Investments、RTW Investments及Coastlands Capital跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1145924428","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145924428?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:31","pubTimestamp":1782819110,"startTime":"0","endTime":"0","summary":"Pyxis Oncology, Inc.宣布完成一轮融资，本轮融资由BVF Partners L.P.领投，GordonMD Global Investments、RTW Investments及Coastlands Capital共同参与投资。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131521349","title":"Pyxis Oncology宣布获得高达1.14亿美元私募融资，以推动Micvo通过关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1131521349","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131521349?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:30","pubTimestamp":1782819017,"startTime":"0","endTime":"0","summary":"Pyxis Oncology, Inc. (PYXS) 宣布达成一项私募融资协议，融资总额最高可达1.14亿美元。所筹资金将专项用于推进其主要候选药物Micvo完成关键的临床开发阶段。这笔资金的注入旨在加速该疗法的临床进展，助力其跨越重要的研发节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160576686","title":"Pyxis Oncology第一季度净亏损2327.2万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160576686","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160576686?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:17","pubTimestamp":1778757432,"startTime":"0","endTime":"0","summary":"Pyxis Oncology公布的2026年第一季度财报显示，公司净亏损达到2327.2万美元。同期，其运营亏损为2436万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176867662","title":"Pyxis Oncology公布2026年第一季度财报并推进Micvo项目实现年度关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1176867662","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176867662?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:01","pubTimestamp":1778756493,"startTime":"0","endTime":"0","summary":"Pyxis Oncology, Inc.近日发布了其2026年第一季度的财务业绩，并同步宣布正积极推进其重点候选药物Micvo，旨在实现2026年设定的关键临床开发目标。\n公司本季度的财务数据为后续研发投入提供了支撑。与此同时，针对Micvo的临床开发计划取得了显著进展，各项准备工作正按既定时间表向前推进，为达成年度重要临床里程碑奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107704912","title":"Pyxis Oncology Inc 与Keytruda联合疗法的Micvo 1/2期研究最新数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1107704912","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107704912?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:13","pubTimestamp":1774264393,"startTime":"0","endTime":"0","summary":"Pyxis Oncology Inc 宣布，其与Keytruda联合进行的Micvo 1/2期临床试验的最新数据，预计将在2026年下半年更新。这一进展备受业界关注，可能为相关治疗领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512601711","title":"Pyxis Oncology, Inc.盘中异动 股价大涨5.30%报1.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512601711","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512601711?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:15","pubTimestamp":1739898957,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日01时15分，Pyxis Oncology, Inc.股票出现异动，股价大幅上涨5.30%。截至发稿，该股报1.39美元/股，成交量30.5196万股，换手率0.51%，振幅7.20%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190115579627b2a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190115579627b2a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510334593","title":"Pyxis Oncology, Inc.盘中异动 临近午盘股价大跌5.26%报1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510334593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510334593?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:34","pubTimestamp":1739291682,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时34分，Pyxis Oncology, Inc.股票出现异动，股价快速下挫5.26%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.51%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Dominari Holdings Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2898.52%、1277.81%、427.55%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为78.52%、59.46%、58.60%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212003442961f5d52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212003442961f5d52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510987869","title":"Pyxis Oncology, Inc.盘中异动 早盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510987869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510987869?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:16","pubTimestamp":1739200592,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时16分，Pyxis Oncology, Inc.股票出现异动，股价大幅跳水5.00%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210231632a240aca3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210231632a240aca3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505431330","title":"Pyxis Oncology, Inc.盘中异动 早盘快速上涨5.13%报1.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505431330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505431330?lang=zh_cn&edition=full","pubTime":"2025-01-24 00:19","pubTimestamp":1737649160,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日00时19分，Pyxis Oncology, Inc.股票出现波动，股价快速拉升5.13%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Exicure, Inc.涨幅较大，Hepion Pharmaceuticals, Inc.、Dogwood Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为3544.69%、1684.14%、651.17%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Jupiter Neurosciences, Inc.，振幅分别为186.07%、64.29%、55.57%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124001920960e59a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124001920960e59a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504949849","title":"Pyxis Oncology, Inc.盘中异动 下午盘股价大跌5.10%报1.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504949849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504949849?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:46","pubTimestamp":1737053182,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时46分，Pyxis Oncology, Inc.股票出现异动，股价快速下挫5.10%。截至发稿，该股报1.40美元/股，成交量38.7214万股，换手率0.65%，振幅4.85%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117024622abad8695&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117024622abad8695&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503685942","title":"Pyxis Oncology, Inc.盘中异动 下午盘股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503685942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503685942?lang=zh_cn&edition=full","pubTime":"2025-01-15 03:50","pubTimestamp":1736884253,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日03时50分，Pyxis Oncology, Inc.股票出现波动，股价快速跳水5.23%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115035053a221fa7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115035053a221fa7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502898376","title":"Pyxis Oncology, Inc.盘中异动 股价大跌5.59%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502898376","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502898376?lang=zh_cn&edition=full","pubTime":"2025-01-10 23:09","pubTimestamp":1736521792,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日23时09分，Pyxis Oncology, Inc.股票出现波动，股价快速下挫5.59%。截至发稿，该股报1.52美元/股，成交量18.5536万股，换手率0.31%，振幅3.73%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.33%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102309529861f25d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102309529861f25d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501745707","title":"Pyxis Oncology, Inc.盘中异动 早盘大幅下跌5.12%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501745707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501745707?lang=zh_cn&edition=full","pubTime":"2025-01-08 22:44","pubTimestamp":1736347460,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日22时44分，Pyxis Oncology, Inc.股票出现异动，股价快速跳水5.12%。截至发稿，该股报1.65美元/股，成交量6.8903万股，换手率0.12%，振幅3.45%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010822442195fd0174&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010822442195fd0174&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500978898","title":"Pyxis Oncology, Inc.盘中异动 急速上涨5.13%报1.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500978898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500978898?lang=zh_cn&edition=full","pubTime":"2025-01-02 22:32","pubTimestamp":1735828365,"startTime":"0","endTime":"0","summary":"北京时间2025年01月02日22时32分，Pyxis Oncology, Inc.股票出现异动，股价大幅拉升5.13%。截至发稿，该股报1.64美元/股，成交量3.6112万股，换手率0.06%，振幅2.56%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102223245ab9bf68d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102223245ab9bf68d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493087055","title":"Pyxis Oncology, Inc.盘中异动 急速下挫5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493087055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493087055?lang=zh_cn&edition=full","pubTime":"2024-12-24 22:48","pubTimestamp":1735051685,"startTime":"0","endTime":"0","summary":"北京时间2024年12月24日22时48分，Pyxis Oncology, Inc.股票出现波动，股价大幅下挫5.39%。Pyxis Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Pyxis Oncology, Inc.公司简介：Pyxis Oncology Inc 是一家临床前肿瘤学公司，致力于开发一系列针对难治癌症的新一代治疗药物，改善患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122422480595eb2832&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122422480595eb2832&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PYXS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pyxisoncology.com","stockEarnings":[{"period":"1week","weight":-0.144},{"period":"1month","weight":0.1063},{"period":"3month","weight":0.7526},{"period":"6month","weight":1.1623},{"period":"1year","weight":0.7526},{"period":"ytd","weight":1.8957}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pyxis Oncology, Inc.于2018年6月11日在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司，推进专注于解决实体瘤患者未满足的医疗需求的发展战略，并立即关注头颈部鳞状细胞癌（HNSCC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.283554},{"month":2,"riseRate":0.6,"avgChangeRate":0.106698},{"month":3,"riseRate":0.2,"avgChangeRate":-0.016511},{"month":4,"riseRate":0.6,"avgChangeRate":-0.065271},{"month":5,"riseRate":0.8,"avgChangeRate":0.019792},{"month":6,"riseRate":0.2,"avgChangeRate":0.044987},{"month":7,"riseRate":0.8,"avgChangeRate":0.040826},{"month":8,"riseRate":0.4,"avgChangeRate":0.030931},{"month":9,"riseRate":0.4,"avgChangeRate":0.080791},{"month":10,"riseRate":0.25,"avgChangeRate":0.090516},{"month":11,"riseRate":0.2,"avgChangeRate":-0.058552},{"month":12,"riseRate":0.2,"avgChangeRate":-0.217409}],"exchange":"NASDAQ","name":"Pyxis Oncology, Inc.","nameEN":"Pyxis Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pyxis Oncology, Inc.(PYXS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pyxis Oncology, Inc.(PYXS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pyxis Oncology, Inc.,PYXS,Pyxis Oncology, Inc.股票,Pyxis Oncology, Inc.股票老虎,Pyxis Oncology, Inc.股票老虎国际,Pyxis Oncology, Inc.行情,Pyxis Oncology, Inc.股票行情,Pyxis Oncology, Inc.股价,Pyxis Oncology, Inc.股市,Pyxis Oncology, Inc.股票价格,Pyxis Oncology, Inc.股票交易,Pyxis Oncology, Inc.股票购买,Pyxis Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pyxis Oncology, Inc.(PYXS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pyxis Oncology, Inc.(PYXS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}